Folkehelseinstituttet [the Norwegian Institute of Public Health] has held an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups for the seasons 2022/2023. Two sub-contracts have been entered into, where total contract volume is distributed 60% to service provider no. 1 and 40% to service provider no. 2.

Folkehelseinstituttet [the Norwegian Institute of Public Health] has held an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition was the lowest price. The tender documentation had several minimum requirements for the vaccination. All the minimum requirements must be fulfilled.

The procurement was carried out in accordance with the Public Procurement Act (PPA) of 17 June 2016 and the Public Procurement Regulations (PPR) part I and part III of 12 August 2016. Contract award was done in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

Prior to announcement of the contest, the Norwegian Institute of Public Health received signals that there would be significant risk that doses could not be allocated to Norway if the procurement process was not carried out before the middle of December. As the Norwegian Institute of Public Health could not risk Norway being left without doses, it was decided to hold the contest with a 15 day tender deadline. Incidentally, the procurement was carried out in-line with the procurement regulations.

The total contract volume was previously estimated at 700,000 - 900,000 doses

In this contest, in consideration of preparedness, the Norwegian Institute of Public Health awarded two sub-contracts where the total volume is divided as follows:

60% of total volume, 516,000 doses, Sanofi Aventis Norge AS

40% of total volume, 344 000 doses, Viatris AS

The award was done in-line with the Tender Documentation Chapter 6 ‘Award Criteria’ and sub-points.

First delivery in the new contract is anticipated to be before 20 September 2022.

Folkehelseinstituttet [the Norwegian Institute of Public Health] has held an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition was the lowest price. The tender documentation had several minimum requirements for the vaccination. All the minimum requirements must be fulfilled.

The procurement was carried out in accordance with the Public Procurement Act (PPA) of 17 June 2016 and the Public Procurement Regulations (PPR) part I and part III of 12 August 2016. Contract award was done in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

Prior to announcement of the contest, the Norwegian Institute of Public Health received signals that there would be significant risk that doses could not be allocated to Norway if the procurement process was not carried out before the middle of December. As the Norwegian Institute of Public Health could not risk Norway being left without doses, it was decided to hold the contest with a 15 day tender deadline. Incidentally, the procurement was carried out in-line with the procurement regulations.

The total contract volume was previously estimated at 700,000 - 900,000 doses

In this contest, in consideration of preparedness, the Norwegian Institute of Public Health awarded two sub-contracts where the total volume is divided as follows:

60% of total volume, 516,000 doses, Sanofi Aventis Norge AS

40% of total volume, 344 000 doses, Viatris AS

The award was done in-line with the Tender Documentation Chapter 6 ‘Award Criteria’ and sub-points.

First delivery in the new contract is anticipated to be before 20 September 2022.